Nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic Breast cancer: Results from the tnAcity trial

Annals of Oncology

Volumn 29, Issue 8, 2018, Pages 1763-1770

  Yardley, D A ^a   Coleman, R ^b   Conte, P ^c   Cortes, J ^d,e   Brufsky, A ^f   Shtivelband, M ^g   Young, R ^g   Bengala, C ^h   Ali, H ⁱ   Eakel, J ^j   Schneeweiss, A ^k   De La Cruz Merino, L ^l   Wilks, S ^m   O'Shaughnessy J ^m   Gluck S ⁿ   Li, H ⁿ   Miller, J ⁿ   Barton, D ⁿ   Harbeck, N ^o  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF PADOVA   (Italy)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e VALL D'HEBRON INSTITUTE OF ONCOLOGY   (Spain)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g Center for Cancer and Blood Disorders   (United States)

^h Misericordia Hospital   (Italy)

ⁱ HENRY FORD HEALTH SYSTEM   (United States)

^j Oncology Hematology Consultants   (United States)

^k UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^l HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^m TEXAS ONCOLOGY   (United States)

ⁿ CELGENE CORPORATION   (United States)

^o UNIVERSITY OF MUNICH   (Germany)

more..

Author keywords

Chemotherapy; Gemcitabine; Nab paclitaxel; Triple negative Breast cancer

Indexed keywords

CARBOPLATIN; GEMCITABINE; PACLITAXEL; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ADULT; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; ADJUVANT CHEMOTHERAPY; ADVERSE EVENT; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MASTECTOMY; MIDDLE AGED; MORTALITY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROCEDURES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MASTECTOMY; MIDDLE AGED; PACLITAXEL; PROGRESSION-FREE SURVIVAL; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 85055535644     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdy201     Document Type: Article

References (27)

1. American Cancer Society. Breast Cancer Facts & Figures 2015-2016. Atlanta, GA: American Cancer Society 2015.
2. Hudis CA, Gianni L. Triple-negative Breast cancer: an unmet medical need. Oncologist 2011; 16(Suppl 1): 1–11.
3. Bauer KR, Brown M, Cress RD et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive Breast cancer, the so-called triple-negative phenotype. Cancer 2007; 109(9): 1721–1728.
4. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative Breast cancer. J Clin Oncol 2008; 26(8): 1275–1281.
5. Dent R, Trudeau M, Pritchard KI et al. Triple-negative Breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13(15 Pt 1): 4429–4434.
6. Lin NU, Claus E, Sohl J et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative Breast cancer: high incidence of central nervous system metastases. Cancer 2008; 113(10): 2638–2645.
7. Lehmann BD, Bauer JA, Chen X et al. Identification of human triple-negative Breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121(7): 2750–2767.
8. Chacón RD, Costanzo MV. Triple-negative Breast cancer. Breast Cancer Res 2010; 12(Suppl 2): S3.
9. O’Shaughnessy J, Osborne C, Pippen JE et al. Iniparib plus chemotherapy in metastatic triple-negative Breast cancer. N Engl J Med 2011; 364(3): 205–214.
10. O’Shaughnessy J, Schwartzberg L, Danso MA et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative Breast cancer. J Clin Oncol 2014; 32(34): 3840–3847.
11. Karginova O, Siegel MB, Van Swearingen AE et al. Efficacy of carboplatin alone and in combination with ABT888 in intracranial murine models of BRCA-mutated and BRCA-wild-type triple-negative Breast cancer. Mol Cancer Ther 2015; 14(4): 920–930.
12. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: Breast cancer. version 2.2017. https://www.nccn.org/professionals/physician_gls/pdf/Breast.pdf (18 June 2018, date last accessed).
13. Cardoso F, Costa A, Senkus E et al. 3rd ESO–ESMO international consensus guidelines for advanced Breast cancer (ABC 3). Ann Oncol 2017; 28(1): 16–33.
14. Sledge GW, Neuberg D, Bernardo P et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic Breast cancer: an intergroup trial (E1193). J Clin Oncol 2003; 21(4): 588–592.
15. Rugo HS, Barry WT, Moreno-Aspitia A et al. Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic Breast cancer: CALGB 40502/NCCTG N063H (alliance). J Clin Oncol 2015; 33(21): 2361–2369.
16. Hamilton E, Kimmick G, Hopkins J et al. Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic Breast cancer. Clin Breast Cancer 2013; 13(6): 416–420.
17. Lobo C, Lopes G, Baez O et al. Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic Breast cancer. Breast Cancer Res Treat 2010; 123(2): 427–435.
18. Yardley DA, Brufsky A, Coleman RE et al. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative Breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials 2015; 16(1): 575.
19. Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative Breast cancer. Cancer Biol Med 2015; 12(2): 106–116.
20. Egger SJ, Willson ML, Morgan J et al. Platinum-containing regimens for metastatic Breast cancer. Cochrane Database Syst Rev 2017; 6: CD003374.
21. Tutt A, Ellis P, Kilburn L. Abstract S3-01: the TNT trial: a randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple-negative or BRCA1/2 Breast cancer. Cancer Res 2015; 75.
22. Hu XC, Zhang J, Xu BH et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative Breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 2015; 16(4): 436–446.
23. Gluz O, Nitz U, Christgen M et al. Efficacy of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative Breast cancer: WSG-ADAPT TN randomized phase II trial. J Clin Oncol 2015; 15(33 Suppl): 1032.
24. Yao H, He G, Yan S et al. Triple-negative Breast cancer: is there a treatment on the horizon? Oncotarget 2017; 8(1): 1913–1924.
25. Miles D, Diéras V, Cortés J et al. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic Breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol 2013; 24(11): 2773–2780.
26. Robson M, Im SA, Senkus E et al. Olaparib for metastatic Breast cancer patients with a germline BRCA mutation. N Engl J Med 2017; 377(6): 523–533.
27. Adams S, Diamond JR, Hamilton EP et al. Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative Breast cancer (mTNBC). J Clin Oncol 2016; 34(Suppl 15): 1009.